Evidence map›Paper›PMID 21947834›Full record

GuidelineJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Ethan Basch, Ann Alexis Prestrud, Paul J Hesketh, Mark G Kris, Petra C Feyer, Mark R Somerfield, Maurice Chesney, Rebecca Anne Clark-Snow, Anne Marie Flaherty, Barbara Freundlich and 5 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract readPractice GuidelineSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02939287 (Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients), which is not on this map. Cited by 326 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
326citing papers in PubMed, 16 pooled it
79.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02939287 phase3completednot on this mapstarted 2017, after this paper: background citation

Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients

TypeinterventionalSponsorRush University Medical CenterRan2017 to 2022Enrolled52ConditionsNausea, VomitingArmso Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Aprepitant plus Olanzapine
3 · Its place in the literature

Who cites it

326 citing papers in PubMed, 16 syntheses or guidelines pooled it, 1,054 citations in OpenAlex.

  1. Pooled it
  2. Clinical benefits of adding olanzapine to 5-HTInternational journal of clinical oncology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Aprepitant and fosaprepitant drug interactions: a systematic review.British journal of clinical pharmacology · 2017
    Pooled it
  9. Pooled it
  10. A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017
    Pooled it
  11. Pooled it
  12. Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Pooled it
  13. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Trial

266 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Dosage error in article text
5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Ethan BaschMemorial Sloan-Kettering Cancer Center, New York, USA.
Ann Alexis Prestrud
Paul J Hesketh
Mark G Kris
Petra C Feyer
Mark R Somerfield
Maurice Chesney
Rebecca Anne Clark-Snow
Anne Marie Flaherty
Barbara Freundlich
Gary Morrow
Kamakshi V Rao
Rowena N Schwartz
Gary H Lyman
American Society of Clinical Oncology
Vivantes Klinikum · DE

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
UNIVERSITY OF ROCHESTER--CCOP RESEARCH BASEU10CA037420 · NCI · UNIVERSITY OF ROCHESTER · PI MORROW, GARY R · 1985 to 2014
$21.1M
Tracking Symptoms during Chemotherapy via Online Patient Self-reportingK07CA124851 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BASCH, ETHAN M. · 2008 to 2012
$769k
NCI NIH HHS K07 CA124851NCI NIH HHS U10 CA037420NCI NIH HHS UG1 CA189961
6 · The paper itself

Abstract

purposeTo update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology.

methodsA systematic review of the medical literature was completed to inform this update. MEDLINE, the Cochrane Collaboration Library, and meeting materials from ASCO and the Multinational Association for Supportive Care in Cancer were all searched. Primary outcomes of interest were complete response and rates of any vomiting or nausea.

resultsThirty-seven trials met prespecified inclusion and exclusion criteria for this systematic review. Two systematic reviews from the Cochrane Collaboration were identified; one surveyed the pediatric literature. The other compared the relative efficacy of the 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonists. RECOMMENDATIONS: Combined anthracycline and cyclophosphamide regimens were reclassified as highly emetic. Patients who receive this combination or any highly emetic agents should receive a 5-HT(3) receptor antagonist, dexamethasone, and a neurokinin 1 (NK(1)) receptor antagonist. A large trial validated the equivalency of fosaprepitant, a single-day intravenous formulation, with aprepitant; either therapy is appropriate. Preferential use of palonosetron is recommended for moderate emetic risk regimens, combined with dexamethasone. For low-risk agents, patients can be offered dexamethasone before the first dose of chemotherapy. Patients undergoing high emetic risk radiation therapy should receive a 5-HT(3) receptor antagonist before each fraction and for 24 hours after treatment and may receive a 5-day course of dexamethasone during fractions 1 to 5. The Update Committee noted the importance of continued symptom monitoring throughout therapy. Clinicians underestimate the incidence of nausea, which is not as well controlled as emesis.

Indexed as

AntiemeticsAntineoplastic AgentsAprepitantDexamethasoneDrug Administration ScheduleHumansInfusions, IntravenousIsoquinolinesMorpholinesNauseaNeurokinin-1 Receptor AntagonistsPalonosetronQuinuclidinesRadiotherapySerotonin AntagonistsSurveys and QuestionnairesAntiemeticsAntineoplastic AgentsAprepitantDexamethasonefosaprepitantIsoquinolinesMorpholinesNeurokinin-1 Receptor AntagonistsPalonosetronQuinuclidinesSerotonin Antagonists

Identifiers

PMID21947834
PMCPMC4876353
OpenAlexW2123267000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.